Aptahem receives patent protection in China for patent family 2
Idag, 08:52
Aptahem receives patent protection in China for patent family 2
Aptahem AB (publ) announces today that the company has received patent protection in China for patent family 2 from the Chinese Patent Office.
With the approval in China of patent application 2018800643106, the protection of the company’s drug candidate Apta-1 within patent family 2 in China, Chinese Patent No. 111386121, is valid until the end of 2038.
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
About Aptahem
Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.
Ämnen i artikeln
Aptahem receives patent protection in China for patent family 2
Idag, 08:52
Aptahem receives patent protection in China for patent family 2
Aptahem AB (publ) announces today that the company has received patent protection in China for patent family 2 from the Chinese Patent Office.
With the approval in China of patent application 2018800643106, the protection of the company’s drug candidate Apta-1 within patent family 2 in China, Chinese Patent No. 111386121, is valid until the end of 2038.
For further information:
Aptahem AB
Mikael Lindstam, CEO
Tel: +46 (0)766-33 36 99
E-mail: ml@aptahem.com
About Aptahem
Aptahem AB (APTA) is a clinical stage biotechnology company that develops RNA-based pharmaceuticals for the treatment of acute, life-threatening conditions in which a combination of coagulation, inflammation and tissue damage are involved. The company’s lead candidate, Apta-1, is currently in early clinical phase. Apta-1 has in preclinical studies, by its anti-thrombotic, immunomodulating and tissue repairing characteristics, shown very positive and promising results as treatment for sepsis and critical conditions associated with sepsis. For more information, please visit www.aptahem.com.
Ämnen i artikeln
Aktierekar
Bostadsmarknaden
Intellego-härvan
Analyser
Inflationen
-950x950.webp&w=3840&q=75)
AI
Aktierekar
Bostadsmarknaden
Mest läst
Intellego-härvan
Analyser
Inflationen
AI
Marknadsöversikt
1 DAG %
Senast
1 mån
